Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the EANO

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review, we present these guidelines, which provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, we address aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.

click here for published version (published in The Lancet Oncology, Volume 16, ISSUE 7, Pe322-e332, July 01, 2015 DOI:https://doi.org/10.1016/S1470-2045(15)00076-5)

EANO Conflict of Interest Disclosure

Declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided. Declarations must include any payments, honorarium or arrangement for re-imbursement of expenses, relevant for any aspect of his/her involvement with EANO, that has been provided by commercial companies.

Log in to edit your data

Login